Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled study of lumateperone tosylate capsules in adults with acute exacerbation of schizophrenia
CTR20253432Phase 3Active
- Sponsor
- Rongchang Pharmaceuticals
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lumateperone in schizophrenia, sponsored by Rongchang Pharmaceuticals. Started Aug 2025; status: active.
02
Drugs
lumateperone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20253432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253432.